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ABSTRACT 
Background:  Research in animal models suggests that fish oil 
ingestion may impair immunity and increase risk for infection. To date 
there are no studies examining this relationship between fish oil ingestion 
and risk for infection in humans.  
Objective:  The primary aim of this randomized, placebo-controlled, 
double-blind, parallel-arm study was to examine the effect of 400 mg of 
EPA and 200 mg of DHA, the main components of fish oil (FO) 
supplements, on the incidence of symptoms related to upper respiratory 
tract infections in healthy young females, at a large southwestern 
university.
 Design:  Healthy young women between 18 and 38 years of age 
who were non-obese (mean BMI 23.7 ± 0.6 kg/m2) were recruited from an 
urban southwestern university campus. Subjects were non-vegetarians, 
non-smokers, and reported consuming less than one serving (3.5 oz) of 
fish per week. Participants (n=26) were randomized according to age, 
body weight, BMI, and daily n-3 fatty acid (FA) intake into two groups:  FO 
(one gel capsule of 600 mg EPA/DHA per day) or CO (one placebo gel 
capsule of 1000 mg coconut oil per day). Participants completed a 
validated daily cold symptom survey, the Wisconsin Upper Respiratory 
Symptom Survey-21 for 8 weeks. Fasting blood samples measuring TNF-
α concentrations were taken at weeks 1 and 8, when 24-hour dietary 
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recalls were also performed. Anthropometric measurements were 
recorded via bioelectrical impedance at trial weeks 1, 4, and 8. 
 Results:  The 8-week trial of FO supplementation did not 
significantly change the average score for perception of cold symptoms 
between FO and CO groups (167 ± 71 and 185 ± 56, p=0.418, 
respectively). Plasma TNF-α levels (pg/mL) did not differ between groups 
(p=0.482). TNF-α levels were significantly correlated with body weight 
(r=0.480, p=0.037), BMI (r=0.481, p=0.037, and percent body fat (r=0.511, 
p=0.025) at baseline. 
 Conclusions: Healthy young women taking a fish oil supplement of 
400 mg EPA and 200 mg DHA per day over 8 weeks does not impose 
unintentional health consequences. These findings do not refute the 
American Heart Association’s current recommendations for all Americans 
to consume two servings (3.5 oz) of a variety of oily fish per week. 
Depending on the type of fish, this current recommendation equates to 
approximately 200-300 mg per day of EPA and DHA n-3 polyunsaturated 
fatty acids. Additional research is needed to investigate the effects of 
higher dosages of fish oils on daily cold symptoms. 
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Chapter 1
INTRODUCTION
In a 2007 national survey, 17.7 percent of American adults reported 
using a natural dietary supplement for health reasons, one that is not 
classified as either a vitamin or mineral (1). Natural remedies for the 
common cold such as Echinacea are likely to reduce the severity of 
respiratory tract infections however scattered reports show that some 
dietary supplements actually promote these infections (2,3). Supplements 
derived from fish oil, containing the essential fatty acids eicosapentaneoic 
acid (EPA) and docosahexaneoic acid (DHA), are the most commonly 
used natural supplement, used by 37.4 percent of Americans (1). 
The anti-inflammatory effects of EPA and DHA in fish oil may have 
a beneficial role in reducing inflammation in chronic inflammatory diseases 
such as Crohn’s disease, rheumatoid arthritis (4), and inflammatory bowel 
disease (5,6). There is also evidence, based on epidemiological and 
controlled-clinical trial research, that supports reduced cardiovascular 
disease incidences with omega-3 fatty acids (7). As part of a heart-healthy 
diet the American Heart Association recommends eating two 3.5 ounce 
servings of fish per week (8). Fish oil recommendations are also being 
promoted in popular media outlets such as the Dr. Oz show, which lists 
omega-3 fish oils as one of the top five supplements all women should 
take (9). Although there is support for the beneficial effects of fish oils in 
some chronic diseases, the fish oils EPA and DHA have 
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immunosuppressive effects that have been shown to increase 
susceptibility to infections in animals (10-12).
Schwerbrock et al. (12) noted that fish oil-fed mice had an 
increased mortality, increased viral load, and prolonged recovery period 
after influenza infection. Byleveld et al. (10,11) observed that mice fed fish 
oil diets had delayed viral clearance and decreased cytotoxic T cell 
activity. While these studies have indicated that fish oil supplementation is 
hazardous to the health of mice with influenza virus, a suppressed 
immune response has also been observed in mice consuming omega-3 
polyunsaturated fatty acids (PUFAs) inoculated with Listeria 
monocytogenes and Mycobacterium tuberculosis (13,14). Although the 
prior literature suggests an ill-adaptive response for influenza viral 
clearance in fish-oil fed mice (10-12,14), there is a deficiency in the 
literature that looks at the immune response to cold and flu viruses in 
healthy humans consuming fish oil supplements. With the heightened 
awareness of omega-3 PUFAs to stop inflammation, it is not yet clear 
whether these dietary supplements can increase susceptibility to 
infections in healthy human subjects. 
Research has shown a significant decrease of lymphocyte 
proliferation in healthy individuals consuming fish oil supplements 
containing as little as 1 g of EPA per day (15). Additional support of dietary 
omega-3 PUFAs delaying the immune response has been observed in 
slowed wound healing of blisters in individuals taking 1.6 g of EPA and 1.1 
2
g of DHA for 4 weeks (16). These randomized, placebo-controlled, double-
blinded studies suggest fish oil supplements may have detrimental effects 
on the immune system which raises concern since alternative medicine 
therapies are on the rise in the United States (1). 
Purpose of the Study
The primary aim of this randomized, placebo-controlled, double-
blind, parallel-arm study was to examine the effect of 400 mg of EPA and 
200 mg of DHA, the main components of fish oil supplements, on the 
incidence of symptoms related to upper respiratory tract infections in 
healthy females, aged 18-40, at a large southwestern university. 
Hypothesis
 We hypothesized that self-reported levels of cold symptoms will 
increase in the fish oil supplement group compared to a placebo-control 
group. This study coincided with the highest occurrences of cold and flu 
symptoms which appear in January and February in the United States 
(17).
Definition of Terms 
• BMI:  [weight (in pounds) / height (in inches) x height (in inches)] x 
703; < 18.5 is underweight, 18.5-24.9 is normal, 25.0-29.9 is 
overweight, and > 30 is obese (18).
• Common cold:  an acute respiratory illness caused by viral infection 
of the upper respiratory tract. Symptoms typically appear one to 
three days after exposure to a cold virus. Symptoms are mild and 
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include runny or stuffy nose, sore throat, cough, sneezing, and 
congestion (19,20). 
• Fish oil:  derived from marine sources which are rich in the long-
chain omega-3 PUFAs EPA (20:5n-3) and DHA (22:6n-3) (7).
• Healthy:  no unresolved health conditions. Some prescription 
medications were excluded such as thyroid medications for an 
accompanying study and also any anti-inflammatory medications, 
e.g., corticosteroids. 
• Regular smoker:  greater than or equal to 10 cigarettes per day 
(21).
• Training athlete:  engaged in purposeful exercise five or more times 
per week.
• Vegetarian:  excludes all meat, fish, and poultry products from diet.
Limitations
• Subject compliance to protocol includes administration of 1 
supplement and completing the cold symptom survey daily.
• Recording of dietary sources of omega-3 fatty acids occurred via a 
validated food frequency questionnaire (FFQ) specific to sources 
rich in omega-3 fatty acids.
• External factors such as lack of sleep or psychological stress may 
impact inflammatory state and susceptibility to infection.
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• Short trial duration (8 weeks) may not accurately reflect the 
duration of the 2011-2012 cold and flu season and may not show 
any long-term physiological effects of omega-3 fatty acids.
• A small subject pool (n=26) limit the generalizability of the results 
and obtaining statistical significance.
• Study does not observe detailed mechanisms to determine specific 
mediators in the immune response.
• Perception of cold symptoms is a subjective measure. People may 
have different tolerances impacting their self-reported responses on 
the questionnaire.
• Cannot control exposure to cold and flu viruses.
Delimitations 
 Participants were limited to healthy college women, aged 18-38 
years from a large southwestern university in the United States with BMI 
between 18.5 and 30. Exclusion criteria for the study included participants 
who are regular smokers, women who are pregnant or lactating, those 
who consume greater than or equal to 1 serving of fish per week, regular 
use of fish oil supplements, regular use of thyroid medication, 
corticosteroids and/or non-steroidal anti-inflammatory drugs, vegetarians, 
training athletes and/or individuals who are trying to lose or gain weight, 
those who have allergies to seafood, and individuals who have received a 
flu shot for the 2012 season. 
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Chapter 2
LITERATURE REVIEW
Fish Oils Overview 
Western Diets & Fatty Acid Ratio. Dietary patterns in developed 
nations are associated with a high consumption of pro-inflammatory 
omega-6 (n-6) PUFAs and a reduced consumption of anti-inflammatory 
omega-3 (n-3) PUFAs (22). The ratio of n-6 to n-3 PUFAs in the Western 
diet is now 15 times greater than the diet humans have evolved upon in 
the past (23). The dietary intake of n-6 to n-3 PUFAs was much more 
balanced in hunter-gatherer societies with an estimated n-6:n-3 ratio of 1:1 
(24). The ratio of n-6 to n-3 PUFAs has increased to 16-20:1 in the current 
Western diet and is a likely contributor to an increased incidence of CVD 
and inflammatory disorders (22,25,26). 
The n-3 fatty acids, α-linolenic acid (ALA), EPA, and DHA compete 
as substrates for the prostaglandin pathway with the n-6 fatty acids, e.g. 
arachidonic acid (AA). Anti-inflammatory mediators increase with n-3 fatty 
acid consumption concomitant with decreases in the inflammatory 
mediators (5,27). The impact of the dietary ratio of n-3 and n-6 PUFAs is 
dose-dependent, modifies cellular composition within a few days, and 
reaches a new steady-state in up to four weeks (27). High intakes of n-6 
PUFAs increase AA in the plasma and cell membranes and lead to the 
increased production of pro-inflammatory metabolites (22). The high n-6 to 
n-3 ratio is potentially linked to the pathogenesis of chronic diseases such 
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as cardiovascular diseases (CVD), inflammatory, and autoimmune 
disorders (22,23,25,28). Inflammatory and autoimmune disorders are 
characterized by elevated levels of the pro-inflammatory cytokine, 
interleukin 1 (IL-1) which is promoted by n-6 fatty acids (26).
Surveys from cross-sectional and epidemiologic research found an 
inverse correlation with n-3 fatty acid status and prevalence rates of CVD 
and depression. In 1996 the annual seafood consumption, assessed by 
pounds per person, was about three-fold higher in Japan (148 lb/person) 
compared to the United States (48 lb/person) (29). Statistics from the 
World Health Organization in 2008 showed the prevalence of CVD 
mortality among men aged 45-59 differed among regions such as Eastern 
(e.g., Japan and Singapore) and Western regions (e.g., United States and 
Canada). The Eastern region (23/100,000) had a 60% lower risk of CVD 
mortality compared to the Western region (37/100,000) (30). 
Geographic regions have differing risk factors for CVD and n-3 fatty 
acid status. Counterintuitive to the previous report on CVD mortality risk 
among regions, Asian Indians in Singapore have a greater risk of CVD 
than any other ethnic group. The National University of Singapore Heart 
Study in 2004 was a cross-sectional survey which looked at the 
differences of essential fatty acid plasma concentrations among Asian 
Indians and Chinese men in relation to CVD susceptibility. In 292 subjects, 
Asian Indians showed lower total n-3 plasma fatty acid concentrations 
compared to the Chinese (4.71% versus 5.27%, p<0.001) which 
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correlated positively with HDL-C and Apo-A1 concentrations and 
negatively with LDL-C and Apo-B concentrations. These results support 
the premise that high n-3 fatty acid status is associated with cardio-
protective benefits (31).
Other populations world-wide have greater n-3 fatty acid status 
compared to Western cultures. The native Greenland Eskimos’ diets are 
characteristically high in n-3 PUFAs from consuming whales, seals, 
Greenland halibut, and salmon (32). The Eskimo population along with the 
Japanese, have diets high in marine n-3 fatty acids and low incidences of 
myocardial infarction and chronic inflammatory diseases compared to 
Western cultures (26,33). These correlations have been observed since 
1971, when Bang et al. studied Greenland Eskimos who consume high 
amounts of animal fats but have low incidences of CVD compared to 
Danish controls consuming a typical Western diet. It was observed that 
Eskimos had much lower plasma triglycerides (TAG) (p<0.001) and pre-β-
lipoprotein levels than controls (p<0.001) (32). Pre-β-lipoproteins are 
synonymous with very low density lipoproteins (VLDL) produced in the 
liver to transport endogenous TAGs to non-hepatic tissues (34). 
Recently however, the Arctic Inuit populations’ diet is changing in 
response to Western influences. In 2005 the Inuit Health in Transition 
study took a baseline survey of two Inuit populations, the Nunavik in 
northern Quebec and the Greenland Inuit, measuring the fatty acid profile 
of red blood cell phospholipids which is a good indicator of dietary fatty 
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acid intake. The mean total n-3 levels for the Greenland population was 
12.1% compared to 9.4% for the Nunavik (p<0.001). There are many 
occupational, environmental, and generational factors that contribute to 
the complex dietary changes seen in this population, which is reflected in 
their trans fatty acid status. Average trans FA levels were three-fold higher 
in the Nunavik (1.20%) than the Greenland (0.43%) which may explain the 
displacement of n-3 FA consumption in their diets due to high trans FA 
intake (35). 
Inverting the essential fatty acid ratio to favor dietary n-3 fatty acids 
exert immunosuppressive and anti-inflammatory effects in the body (23). 
N-3 fatty acids have anti-atherogenic properties such as decreasing 
platelet aggregation and lowering TAG levels (33). The deficiency of n-3 
PUFAs in Western diets is likely a major contributor to the development of 
chronic diseases although this has not always been the case when 
examining the evolutionary aspect of foods containing EPA and DHA (23). 
 Over the last 100 years, modern agriculture and technological 
advancements in the food industry have contributed to the increased 
consumption of n-6 fatty acids (23,28). Anthropological and epidemiologic 
studies have examined the diet humans have evolved upon which 
indicated a n-6 to n-3 ratio of approximate 1 compared to current Western 
diets estimated near 15.0-16.7 to 1. The progress of increasing essential 
fatty acid ratio coincides with major changes in the type and amount of 
fatty acids consumed and antioxidant content in foods. In the past, the 
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food supply contained omega-3 PUFAs in eggs, meat, fish, wild plants, 
nuts, and berries (36). Theories contributing to the lower n-6 to n-3 ratio in 
hunter-gatherer societies were based on estimated levels of trans-fatty 
acid intake at a fraction of the current 2% of total calories. Also, PUFA 
intake was estimated at nearly twice the current amount (15 g/d) (37). 
Marine-derived fish oils have high concentrations of the n-3 PUFAs, 
EPA and DHA (24,38). Sources of the plant-derived n-3 PUFA, ALA, 
include nuts, seeds, soybean and canola oils (24). Based on the evidence 
discussed above, the dietary balance of essential fatty acids is especially 
important for maintaining good health and development. The increased 
concern in the balance of essential fatty acids and the deficiency of n-3 
fatty acids in Western diets has led to more recommendations to 
supplement the diet with n-3 fatty acids (25).
Biochemistry, Absorption, & Metabolism. The long-chain n-3 and 
n-6 PUFAs are important for their distinctive health functions which are 
due in part to their structure and properties. Unlike plants, humans cannot 
metabolically convert n-6 to n-3 fatty acids because mammals lack the 
omega-3 desaturase enzyme to produce ALA from AA, making them two 
distinct families (23). AA is part of the n-6 fatty acid family along with the 
other n-6 PUFA derivatives ɣ-linolenic acid (GLA), dihomo-ɣ-linolenic acid 
(DGLA), adrenic acid, and docosapentaenoic acid (DPA) which come from 
the precursor linoleic acid (LA). In the n-3 fatty acid family ALA is the 
precursor to the long-chain PUFAs EPA, DPA, and DHA (34,39). 
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Both long-chain PUFAs n-6 and n-3 are digested and efficiently 
absorbed by the small intestine (39). In particular, it was reported that ALA 
has an absorption rate greater than or equal to 96%. Several metabolic 
destinations for n-3 PUFAs include storage in adipose tissue, producing 
energy through β-oxidation, converting into other non-essential fatty acids, 
or enzymatically elongation and desaturation into long-chain PUFAs in the 
liver (22). N-6 PUFAs are metabolized similarly, where they are 
incorporated into phospholipid membranes, used in eicosanoid synthesis, 
or used for energy production via β-oxidation (39). 
LA and ALA are considered essential in the diet because 
mammalian cells lack delta-12-desaturase and delta-15-desaturase which 
insert double bonds in oleic acid to produce LA and ALA (5,34). The 
presence of the elongase and desaturase enzymes for the delta-9 carbon 
and above allow for conversion of ALA and LA into EPA/DHA and AA 
respectively (40). 
The first step in the metabolism of ALA to EPA and DHA is the 
addition of a fourth double bond to produce the intermediate stearidonic 
acid by delta-6-desaturase, which is considered the rate-limiting step. 
Following elongation and additional desaturation from delta-5-desaturase, 
EPA becomes the first product in ALA metabolism. Several other steps of 
elongation and desaturation occur to yield DHA, although only small 
amounts of DHA are produced despite available levels of ALA in body 
tissues. The conversion rate from ALA to EPA in humans is estimated at 
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8-20% whereas conversion from ALA to DHA is even smaller at 0.5-9% 
(22). Ultimately, the elongated n-3 fatty acids get incorporated into the 
cellular phospholipid membranes of all body tissues (22). In the 
phospholipid membrane, EPA produces biologically active eicosanoids 
that have immunosuppressive actions. These anti-inflammatory 
eicosanoids consist of series 5 leukotrienes and series 3 thromboxanes 
and prostaglandins, which exhibit beneficial effects in preventing 
arrhythmias and thrombosis (22,23,39).
LA metabolism into AA competes for the same elongase and 
desaturase enzymes as ALA. In fact, in vitro studies provide evidence that 
delta-6-desaturase has a preference for n-3 fatty acids over n-6 fatty acids  
(39). Dietary LA undergoes a desaturation reaction generating a third 
double bond by delta-6-desaturase to yield GLA. Elongation adds 2 
carbons to GLA to produce DGLA. Delta-5-desaturase undergoes a 
desaturation reaction to produce AA (41). LA metabolizes into AA which is 
an important metabolite, structurally compromising approximately 15% of 
total fatty acids in erythrocyte membranes and is also involved in 
apoptosis (41,42). AA also has a major role as the precursor of many 
eicosanoids such as thromboxanes, prostaglandins, and leukotrienes 
within the cell (43).
 Once incorporated into the phospholipid membranes of the cell, 
AA exhibits strong inflammatory responses mediated by biologically active 
eicosanoids. These metabolic products are involved in platelet 
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aggregation and thrombus formation which contribute to the progression 
of atherogenesis (23,39). To produce eicosanoids, AA first must be 
released from the sn-2 position in phospholipids by phospholipase A2 in 
response to a variety of stimuli. The cyclooxygenase pathway synthesizes 
prostaglandins and thromboxanes whereas 5-lipoxygenase synthesize 
leukotrienes (43). 
Eicosanoids have varying physiologic functions and antagonistic 
effects. Prostacyclin (PGI2) increase cyclic adenosine monophosphate 
(cAMP) activity, thus acts as a platelet anti-aggregating factor. Conversely, 
thromboxane-A2 (TXA2) decreases cAMP activity and promotes platelet 
aggregation. Another opposing pair is prostaglandin E2 (PGE2) which acts 
as a blood vessel vasodilator and prostaglandin F2 (PGF2) which acts as 
a vasoconstrictor (34). These prostaglandins are produced in response to 
their respective fatty acid of the n-6 or n-3 families. AA competes with EPA 
in these metabolic pathways, displaces EPA’s position in phospholipids, 
and invokes an inflammatory response; conversely, EPA metabolic 
products have a much weaker inflammatory response (25). 
Sources & Recommended Intakes. Although ALA is the parent 
compound to all other n-3 fatty acids, EPA and DHA can also be provided 
from ingested fish oils. To produce EPA and DHA, ALA undergoes a series 
of desaturation and elongation steps in the liver. Oily fish such as salmon, 
mackerel, and tuna are rich sources of omega-3 fatty acids EPA and DHA 
(5,25). Different varieties of marine animals have varying amounts of EPA 
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and DHA per serving. For example, sockeye salmon has 600 mg of DHA 
and 450 mg of EPA whereas Atlantic salmon has 950 mg of DHA and 250 
mg of EPA per serving (44). Aside from n-3 fatty acids in animal sources 
there are several plant sources high in the n-3 fatty acid ALA such as 
walnuts, flaxseed, rapeseed, and green leafy vegetables (22). 
As seen in the n-3 family, the parent compound to all other n-6 fatty 
is dietary LA although it too can be provided from the diet in limited 
amounts (39). LA undergoes a similar pathway to produce AA in the liver. 
Dietary sources rich in n-6 fatty acid LA are corn, sunflower, and soybean 
oils (5) and preformed AA is found in small amounts in eggs, animal, and 
organ meats (22,45).
Based on the Dietary Reference Intakes (DRIs) established by the 
National Academy of Sciences, Acceptable Intakes (AIs) and Acceptable 
Macronutrient Distribution Ranges (AMDRs) have been set for essential 
fatty acids. The appropriate n-6 to n-3 ratio is 1-2:1 which is consistent 
with the recommended AIs (23). The AI for adult men 19-50 years, is 17 g/
day of LA and 1.6 g/day of ALA. For adult men 51 years and older the AI is 
14 g/day of LA and also 1.6 g/day of ALA. The AIs for adult women 19-50 
years is 12 g/d of LA and 1.1 g/day of ALA. For adult women ages 51 
years and older, ALA remains the same at 1.1 g/day whereas LA is 11 g/
day. However, for pregnant and lactating women the AI is 13 g/day of LA 
and 1.4 g/day of ALA but during lactation it is slightly lower at 1.3 g/day of 
ALA (39). 
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AMDRs for n-6 and n-3 fatty acids are established based on 
epidemiological and intervention trials to provide sufficient amounts for 
preventing chronic diseases and nutritional deficiencies. To meet the AI for 
LA, the lower and upper boundary level is estimated at 5-10% of total 
energy. Likewise, the AMDR for ALA is an estimated 0.6-1.2% of energy. 
Because EPA and DHA have greater physiologic effects than ALA, a total 
n-3 AMDR cannot be determined therefore, EPA and/or DHA should be 
consumed at 10% of the AMDR for ALA (39). 
 Biological Functions. Long-chain PUFAs have important biological 
functions for growth, reproduction, and neurological development (40). N-3 
fatty acids, EPA, DHA, and ALA are important for brain function and brain 
development especially for newborns (22). There are also vital roles of n-3 
fatty acids for maintaining optimal cardiovascular health and function 
related to their anti-thrombotic, anti-atherogenic, vasoprotective, and anti-
arrhythmic properties (22,46). N-6 fatty acids have been shown to have 
roles in normal epithelial cell function. AA functions as a substrate for 
eicosanoid production and is involved in cell signaling pathways. Aside 
from their physiological function, the long-chain PUFAs play a vital role as 
structural components of phospholipid membranes. They are also involved 
in cell signaling, expressing specific genes that control fatty acid synthesis 
and carbohydrate metabolism. In addition, the fatty acids may also be 
used as ligands for certain receptors that control inflammation, 
neurological function, and the development of adipocytes (39).
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Role in Immune Function. PUFAs are integral to immune function. 
N-3 and n-6 PUFAs are incorporated into the phospholipid membranes of 
immune cells and have different effects on the fluidity and function of the 
cells. Leukocytes have varying functional changes through different 
mechanisms, which are influenced from the composition of dietary fatty 
acids (47). The most studied of such mechanisms are eicosanoid and 
cytokine synthesis, gene expression, lipid rafts, and resolvin synthesis 
(6,40,47).
As n-3 PUFAs are incorporated into immune cell membranes, they 
directly influence the immune response by replacing AA as the precursor 
for eicosanoid synthesis. Likewise, EPA and AA are competitors for the 
same enzymatic pathways (cyclooxygenase and 5-lipoxygenase) to 
produce inflammatory mediators. Compared to AA, eicosanoids produced 
from EPA have a significantly less inflammatory response and include 
prostaglandin E3 (PGE3), leukotriene B5 (LTB5), and series 3 
thromboxanes (47).
The pro-inflammatory eicosanoids from AA include prostaglandin 
E2 (PGE2), leukotriene B4 (LTB4), and series 2 thromboxanes (47). The 
n-3 PUFAs exhibit anti-inflammatory effects through inhibiting the 
production of small proteins called cytokines, which are also immune 
mediators. Pro-inflammatory cytokines are inhibited from n-3 PUFAs at the 
gene-transcriptional level, thus reducing the synthesis of the cytokines 
TNF-α, IL-1β, and IL-6 (47). 
16
Figure 1. Metabolism of Essential Fatty Acids to Eicosanoids
 Source:  http://upload.wikimedia.org/wikipedia/en/0/09/
 EFA_to_Eicosanoid.JPG
EPA and DHA can mediate gene expression of immune cells 
through the activation of nuclear receptors such as the peroxisome 
proliferator-activated receptors (PPARs) (6,40). PPARs are competitors in 
the signaling pathways of the nuclear transcription factor kβ (NF-kβ), a 
regulator of genes involved in inflammation (25,40). The transcribed genes 
involved in the inflammatory response are cytokines, adhesion molecules, 
and other inflammatory mediators (47). PPARs are also responsible for the 
severity and length of the inflammatory response by changing gene 
expression of proteins that catabolize pro-inflammatory eicosanoids 
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(6,47). The indirect effects of n-3 PUFAs on the inflammatory response is 
through inhibiting pro-inflammatory pathways by activating the 
transcription of NF-kβ through toll-like receptors (47).
The alteration of cell membranes by n-3 PUFAs changes the 
fluidity, structure, and function of the receptors in the membranes as well 
as the eicosanoids that are secreted (6). Immune cell activation and 
proliferation uses the lipid rafts to aggregate several receptors. Lipid rafts 
are characteristically rigid in structure because of the included cholesterol 
and saturated fatty acid-rich phospholipids, however the presence of n-3 
fatty acids alters the function through displacement of signaling proteins 
(47). 
Resolvins and neuroprotectins are pro-resolving mediators derived 
from EPA and DHA that are biologically active in reversing inflammation 
(6,48). These mediators were originally discovered showing effects in the 
resolution phase of acute inflammation. There are two bioactive families of 
mediators, Resolvin E series (RvE) and Resolvin D series (RvD), which 
are derived from EPA and DHA, respectively (47,48). RvE1 is associated 
with decreasing pro-inflammatory cytokines IL-6 and TNF-α during the 
resolution phase and also inhibits NF-kβ activity. Neuroprotectin D1 
(NPD1) from the RvD series, synthesized in the brain, is a strong anti-
inflammatory mediator by inhibiting transcription of IL-1β genes in human 
glial cells (47).
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The Immune Response
 Physiology. The immune system is composed of a variety of cell 
types, tissues, and organs. Lymphoid tissues involved in the immune 
response include the thymus, spleen, and lymph nodes (5).
 Immunity. There are two types of defense systems involved in the 
immune response. The innate immune system is present at all times in 
humans and helps defend against pathogens prior to entry and after 
penetration into tissues and fluids. The second class of the immune 
system is adaptive immunity which is alerted in response to a foreign 
antigen that has surpassed the innate immunity. Adaptive immunity can be 
divided into humoral and cellular immune responses which are mediated 
by different lymphocytes (40). Unlike innate immunity, adaptive immunity 
targets specific pathogens and operates quickly at subsequent exposures 
to a memory component. 
 White Blood Cells. Leukocytes are white blood cells involved in the 
immune system that can be further classified into phagocytes and 
lymphocytes (5). Phagocytes are innate immune cells and include the 
granulocytes, monocytes, and macrophages that function to clear 
pathogens as well as tissue debris (48). Lymphocytes are adaptive 
immune cells and are classified as T lymphocytes, B lymphocytes, and 
natural killer cells based on their specific role in immunity (5). B 
lymphocytes are mediators of humoral immunity whereas T lymphocytes 
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mediate cellular immunity through activation of T helper (CD4) or Cytotoxic 
T cells (CD8) (5,40).
 Inflammation. While immunity helps to fight off invading pathogens 
in the body, inflammation is part of the immune response that helps to 
localize the necessary cells and proteins. In response to a reaction, injury, 
or infection, inflammation occurs with the appearance of the classic four 
symptoms:  edema, redness, heat, and pain. Acute inflammation involves 
the neutrophil (PMN) cells in comparison to chronic inflammation which 
involves mononuclear cells (40). Mononuclear cells include macrophages, 
T lymphocytes, and plasma cells (40) which produce cytokines that 
mediate inflammation in the acute phase response (49). The acute phase 
response involves fever, B and T lymphocyte activation, and synthesis of 
acute phase proteins. The following systemic response is a reparative 
phase that involves anorexia, leukocytosis, and other metabolic changes. 
Many of these changes are mediated by the pro-inflammatory cytokines 
IL-1, TNF-α, and IL-6 (5). These cytokines can trigger other immune cells 
to secrete more inflammatory cytokines such as interferon-ɣ and 
interleukin-2 (IL-2) (49). 
 Although pro-inflammatory cytokines have a beneficial purpose in 
fighting off infections, high concentrations of circulating inflammatory 
cytokines are correlated with severe inflammatory conditions such as 
septic shock and meningococcal septic shock (50,51). In other 
inflammatory diseases such as rheumatoid arthritis, Eastgate et al. 
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observed higher concentrations of IL-1 compared to healthy controls 
which correlated with the inflammatory condition (52). It is based on these 
observations that dietary interventions with omega-3 PUFAs may have 
beneficial effects in alleviating chronic inflammatory diseases (49).
 The anti-inflammatory cytokines activate the production of 
eosinophils, mast cells, and immunoglobulin E. Cytokines IL-4, IL-5, and 
IL-10 are produced by Th2 cells in response to the omega-3 fatty acid 
composition in plasma membranes (40). The response of cytokine 
production to typhoid vaccination was investigated before and after 6-8 
weeks of fish oil supplementation (1.15-1.56 g/d of EPA and DHA, 
respectively) in young healthy subjects, showing a reduction of baseline 
IL-1 and IL-6 levels but not in TNF-α. These results however, were not 
significant nor were plasma phospholipid fatty acid concentrations 
measured to assess compliance (53). Additionally, a placebo-controlled 
parallel-arm trial observed similar effects comparing a high-ALA, low-LA 
flaxseed oil-based diet to a low-ALA, high-ALA sunflower-oil based diet 
both supplemented with fish oil (1.6 g/d of EPA and 1.1 g/d of DHA) for 4 
weeks after 4 weeks of modified diets. The authors observed a significant 
inverse relation between EPA content and TNF-α and IL-1β production, 
with EPA concentrations approximately 1% of phospholipid fatty acids. 
These results support the conclusion that n-3 fatty acids suppress 
cytokine TNF-α and IL-1β production (54).
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 Nutritional Effects on Immune System. Vitamins and minerals have 
a profound effect on the immune system whether they are present in 
excessive or deficient amounts. The nutritional status of individuals needs 
to be balanced and adequate in order for the immune system to function 
effectively and optimally. The following nutrients have the most profound 
effect on immunity: dietary fatty acids, vitamins A, B6, B12, C, E, zinc, and 
iron. Multiple nutrient deficiencies negatively affect the immune system 
more than single-nutrient deficiencies (40). 
 Vitamin A status has been extensively studied in association with 
childhood morbidity and mortality since the early 1930’s (55). The Ghana 
VAST Study Team conducted a double-blind, randomized, placebo-
controlled trial with 21,906 children in northern Ghana from 1989 to 1991. 
Children were randomly assigned to groups receiving either 200,000 IU 
retinol equivalents every 4 months or placebos of peanut oil capsules. The 
researchers found that mortality rates due to acute gastroenteritis were 
significantly lower in the vitamin A supplement group than the placebo 
group (p=0.02). In addition, all other mortality causes were lower in the 
vitamin A group than placebo group but not achieving statistical 
significance (56). Vitamin A maintains epithelium integrity in the respiratory 
and gastrointestinal tracts, thus a deficiency can increase the risk of 
infections and relates to 1.2-3 million deaths per year (57). 
 A group of researchers at the Harvard School of Public Health 
analyzed the effect of vitamin A supplementation in children with viral 
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gastroenteritis living in Mexico. In a 10-month trial conducted in 1998, 127 
children less than 2 years of age were enrolled and given a vitamin A 
treatment solution every 2 months (20,000 IU retinol for children younger 
than 12 months of age or 45,000 IU retinol for children 1 year or older). 
Stool samples were collected at least 3 times a month to detect norovirus 
infection. Children in the vitamin A supplement group had significantly less  
(p=0.01) norovirus-associated diarrheal episodes compared to the placebo 
group. These findings indicate the reduced gastrointestinal inflammatory 
response with vitamin A supplementation inhibit the dominant Th1 
response to norovirus infection, thus contributing to lower rates and 
duration of diarrheal symptoms (58). 
 Nutritional supplementation with vitamin D has been observed with 
improved immune response in viral infections with seasonal influenza A. In 
2009, Urashima et al. conducted a 4 month randomized, double-blind, 
placebo-controlled, parallel-arm trial which analyzed 334 children ages 
6-15 years, given 6 tablets daily (1200 IU Vitamin D3 or placebo) during 
the winter months. The incidence of influenza A in children receiving 
vitamin D3 (18 of 167 subjects) was significantly less than children 
receiving the placebo (31 of 167; p=0.04). The investigators reported 
vitamin D3 supplementation may improve innate immunity by enhancing 
antimicrobial peptides and lower inflammation by reducing cytokine 
secretion (59). These nutritional supplement investigations are just a 
glance into the benefits nutritional status’ show in the immune system.
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Upper Respiratory Tract Infections
 Physiology. The respiratory system is made up of organs that are 
involved with the mechanical process of breathing, taking oxygen in 
(inhalation) and expelling carbon dioxide out (exhalation). Air travels from 
the nose all the way to the capillaries in the lungs. Following the pathway, 
air enters through the nose, the nasal cavity, the pharynx (throat), the 
larynx (voice box), and the trachea (windpipe), which divides into two 
bronchial tubes that lead into separate lungs. Each bronchus separates 
further into bronchioles, which terminate into air sacs called alveoli. 
Capillaries in the lungs surround the alveoli where the final exchange of 
gases take place (60).
 The process of respiration takes place at two levels occurring 
simultaneously within the body. External respiration is the exchange of 
gases at the lungs whereas internal respiration involves the exchange of 
gases at the cellular level within all body organs. In external respiration, 
the lungs take in oxygen from an inhalation which passes into the 
capillaries surrounding the alveoli, entering the bloodstream. At the same 
time, carbon dioxide, a gas by-product from cellular metabolism, travels 
from the capillaries into the lungs to be exhaled. With internal respiration, 
oxygen travels from the bloodstream into individual body cells in exchange 
for carbon dioxide which travels through the bloodstream to the lungs for 
exhalation (60).
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 The respiratory tract is characterized by a large surface area  
continually exposed to the external environment which cycles about 10 
liters of air each minute. This feature makes the respiratory tract one of the 
more frequent sites for infections than any other organ (61), therefore 
multiple innate and adaptive immune defense mechanisms exist for 
effective antiviral responses (62). In addition to altering an immune 
response, the nasal cavity has functional defensive roles for trapping large 
particles in the ciliated mucosa (63) or signaling the contraction of 
respiratory muscles to cough or sneeze when irritants are sensed in the 
airways (61). Other functions include the process of air-conditioning which 
warms and moistens the air similar to alveolar conditions and olfaction 
which uses smelling sensors located at the bridge of the nasal cavity (63). 
 Prevalence & Transmission of URTIs. Upper respiratory tract 
infections (URTIs) affects ~ 25 million Americans to visit their primary care 
physicians each year (64). The common cold virus is implicated in 22 
million days of work absences and 20 million days of school absences 
each year, according to the National Center of Health Statistics (65). Due 
to these lost productivity days it is not surprising that the common cold 
attributes to serious economic burdens as well as increased morbidity in 
modern society (66). In the United States, the estimated annual costs of 
acute respiratory illnesses is $40 billion which puts respiratory infections 
as one of the top 10 most costly illnesses (67). 
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 The highest incidences of the common cold appear seasonally. In 
temperate regions of the northern hemisphere, URTIs rise in the autumn, 
remain high throughout winter, and then decrease in the spring (68). On 
average, incidences of the common cold appear more often in children 
than adults. Children usually have 2-6 cold episodes per year whereas 
adults average 1-3 episodes per year (65). A 2005 cohort study reported 
the incidences of URTIs and their effect on general health and academic 
and work performance in 3,249 college adults. Out of those surveyed, 
91% of students reported having at least 1 cold, and 4,263 days of missed 
class were a result of having a URTI (69).
 Transmission of respiratory viruses likely occurs from direct or 
indirect contact with surfaces that have the cold virus on them, then 
touching the eyes or nose. Infection can also occur from inhaling mucus 
droplets suspended in the air filled with the cold virus (65). 
 Infection & Treatment. Although there are over 200 different viruses 
involved in the common cold, the rhinovirus is the most common 
comprising 30-50% of all cold cases each year (65,66). The primary route 
of infection with the rhinovirus in humans is through the eye or the anterior 
nasal mucosa. The rhinovirus then travels to the posterior nasopharynx, 
binds to specific receptors on the endothelial cells where the virus enters 
to start replicating rapidly. The incubation period for rhinovirus ranges from 
1 to 7 days although the type of virus and the health status of the host are 
both factors impacting cold severity (68). In general though, cold 
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symptoms may last from 7 to 14 days with most people recovering within 
10 days (65). 
 Common treatments of URTIs range from herbal supplements such 
as Echinacea, nutritional supplements of vitamin C and zinc, and antiviral 
therapies. A recent study from Johnston et al. observed a significant 
reduction of self-reported cold symptoms among college males consuming 
1000 mg of vitamin C daily compared to controls (70). In studying the 
same variables, a larger randomized, double-blind, population-based 
study observed the relationship between the incidence of common colds 
and vitamin C supplementation. Two intervention groups were analyzed as 
a high-dose (500 mg/day; n=124) group and a low-dose (50 mg/day; 
n=120) group for 5 years. The high-dose vitamin C group experienced 
significantly fewer incidences of colds compared with the low-dose group 
(71). These studies provide evidence that vitamin C supplementation 
protects against the incidence of cold symptoms. 
 The Echinacea plant has been commonly used in the treatment and 
prevention of URTIs and other infections (66). However, the reliability of 
research studies and the variable phytochemical compositions of different 
Echinacea species make it difficult in ascertaining conclusive results 
(66,72). A community-based study analyzed the efficacy of a dried 
encapsulated Echinacea treatment in subjects experiencing current cold 
symptoms and no significant differences were seen between groups (73). 
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 In a similar study design, a randomized, double-blind, placebo-
controlled trial tested the efficacy of Echinilin, a standardized Echinacea 
capsule. Unlike the previous report, this trial used a preparation from 
freshly harvested Echinacea plants composed of alkamides (0.25 mg/mL), 
cichoric acid (2.5 mg/mL), and polysaccharides (25.5 mg/L). Researchers 
found total symptom scores in the Echinacea group to be 23.1% 
significantly lower than the placebo group (p<0.01) (74). Mixed results in 
Echinacea studies may be attributable the variable active phytochemical 
composition, thus more research is needed in this area. On the other 
hand, antiviral drugs may have some beneficial effects but they may have 
adverse side effects and could potentially bring about viral resistance (75). 
 Zinc supplement studies treating URTIs in areas where malnutrition 
is a public health concern, have shown promising effects. A double-blind, 
placebo-controlled 5-month trial observed significantly fewer common cold 
episodes per child (1.37 ± 0.86) in a zinc-supplemented group (10 mg/d, 6 
d/wk) compared with children in the placebo group (3.15 ± 0.55) 
(p<0.001). Although specific mechanisms of how zinc mediates the 
immune response were not discussed, this trial supports the importance of 
zinc for overall immune function in humans (76). 
 Investigations with other nutritional supplements such as vitamin E 
may also improve the immune response. A randomized controlled trial in 
2004 investigated vitamin E supplementation and respiratory tract 
infections among elderly nursing home residents. From 1998 to 2001, 451 
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people completed the 1-year study and were administered a vitamin E 
(200 IU) capsule or placebo capsule daily. Outcome measures included 
incidence of, number of people with, and number of days with upper and 
lower respiratory tract infections. The two groups did not differ statistically 
in the incidence or duration of respiratory tract infections, however a post 
hoc analysis identified fewer people in the vitamin E group contracted 1 or 
more respiratory tract infectionsx with the common cold being the most 
frequent. These results suggest that vitamin E may have protective effects 
against common colds more so than any other respiratory tract infection 
(77).
 Immune System & URTIs. A compromised immune system may 
allow a URTI to persist. For example, prolonged high intensity exercise 
may suppress the immune response through exercise-induced changes in 
stress hormones and cytokine concentrations, (78) increasing the risk of a 
URTI (79). Physical activity may lower natural killer cells, T lymphocytes, 
nasal neutrophil phagocytosis, and mucociliary clearance, all of which 
could increase susceptibility to URTIs (78). Although there are some 
reports that indicate moderate levels of physical activity may decrease the 
risks of respiratory infections. A recent 12-week study by Nieman et al. 
observed the effects of regular physical activity with URTI frequency and 
severity, measured using the reliable WURSS-21 survey. Overall, total 
days with URTI were 43% lower in those who perceived themselves as 
highly physical fit and 46% lower in those who participated in aerobic 
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activity daily. The severity symptoms were reduced 32-41%, respectively 
(80). More evidence using a reliable and valid URTI measures, such as 
the WURSS, are needed to understand the relationship between URTI 
incidence and physical activity levels. 
 Psychological stress may also contribute to immune dysregulation, 
affecting components of the innate and adaptive immune responses. The 
hormone cortisol acts as an indicator of mental stress levels, and some 
studies suggest sleep deprivation restricted to 4 hours per night markedly 
increase cortisol levels higher than sleep restricted to 8 and 12 hours per 
night (81). It is no doubt the type of psychological stress imposed and the 
duration have varying immune dysregularities, which in turn affect ones 
risk for infection (82). However, healthy humans have immune systems 
that are resilient to even large changes in stress-induced immune 
dysfunction, inhibiting susceptibility to infection. The exception is for 
individuals already in a disease-state such as with autoimmune diseases, 
the immune system is inflexible leading to increased vulnerability to 
infections with stress-induced immune responses (83). 
Fish Oils and URIs      
 Immunosuppressive. The most notable immunosuppressive effects 
of dietary n-3 PUFAs have been observed in epidemiological studies of 
the Eskimo population. Large amounts of omega-3 PUFAs are consumed 
in Eskimo populations with decreased incidences of inflammatory 
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diseases compared to Americans (6). Although there appears to be fewer 
incidences of inflammatory diseases, in the past the Inuit population had 
reports of increased incidence of tuberculosis (84). Based on the 
multifactorial influences of genetics and environmental exposure including 
diet, it is difficult to ascertain whether dietary omega-3 fatty acids are 
related to these incidences of infectious diseases (6). 
 Animal studies have extensively studied the effects of FO 
supplementation with infectious disease states. Negative outcomes of 
increased mortality were seen in mice fed high FO diets after infection with 
Salmonella typhimurium compared to coconut oil (CO) fed mice (85). 
Conversely, Blok et al. observed improved survival in FO-fed mice infected 
with Klebsiella pneumoniae compared to palm and corn oil controls after 6 
weeks of supplementation. The amount of oil comprised 15% of their diet 
and showed more significant immune-protective effects in FO-fed mice 
with the lowest infectious dose (86). These variable effects with n-3 fatty 
acids may be reflected in the study designs of supplement duration, type 
of infectious organism, or the amount of diet consumed in animal 
experiments assessing survival rates. 
 The immunosuppressive effects of n-3 fatty acids in humans has 
varied and diverse support for several inflammatory conditions. Most 
studies have observed the effects in patients already in an inflammatory 
state, not taking into account that each disease differs in severity and in 
response to inflammatory mediators. The difficulty in measuring the 
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immunosuppressive effects of n-3 fatty acids involves the subjects’ prior 
health status and the amount and type of n-3 PUFA, which should all be 
taken into consideration. 
 Decreases Lymphocyte Proliferation. There are numerous studies 
examining the effect of dietary n-3 fatty acids on immune cell function, 
specifically measuring lymphocyte proliferation. T lymphocytes are a 
measure of the immune response such as when the white blood cells start 
proliferation it indicates a heightened and alerted immune system. There 
are several studies that examine FO and its effects on the immune 
response. 
 Supplementing n-3 fish oils (1.23 g/d of EPA and DHA) to low-fat 
diets without additional vitamin E for 24 weeks in elderly men and women 
significantly reduced lymphocyte proliferation and in vitro production of 
IL-1β, IL-6, and TNF-α pro-inflammatory cytokines. Conversely, the low-
fat, low-fish diet supplemented with vegetarian sources of n-3 fatty acids 
(0.27 g/d of EPA and DHA) showed moderate increase of these same 
immune response indexes (87). These data suggest that the immune and 
anti-inflammatory effects of n-3 rich diets need to be taken into 
consideration when making recommendations based on population-based 
studies.
 In a 2001 study by Thies et al., 46 healthy older adults aged 56-74 
were randomized into different fatty acid treatment groups, supplementing 
with a placebo of palm and sunflower seed oil blend, ALA, GLA, AA, DHA, 
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or FO (720 mg EPA and 280 mg DHA) for 12 weeks. Total fat intake from 
these capsules was 4 g per day. This was the first study to observe effects  
on the human immune response with a low dose of FO (1 g/d). They did 
not observe significant influences of n-6 or n-3 PUFAs on inflammatory 
cell numbers or ex vivo production of inflammatory cytokines. However, 
significant reductions in plasma soluble adhesion molecule concentrations 
was observed in the FO and ALA supplement groups compared to 
changes seen in the placebo group, which contributes to the reported 
health benefits of n-3 PUFAs. These results suggest that moderate 
increases of n-3 and n-6 PUFAs may not compromise immune function in 
healthy older adults (15). 
 Age may play a factor in the suppression of T lymphocyte 
proliferation with supplementation of 2.4 g of EPA + DHA with 4 mg of 
vitamin E for 3 months. A significant reduction of T lymphocyte proliferation 
was observed in women aged 51-68 years and young women aged 23-33 
years, although greater reductions were seen in older women. This is 
attributable to higher concentrations of EPA and DHA in plasma 
membranes of older women than in younger women (10-fold increase vs 
5-fold increase in EPA and 2.5-fold increase vs 1.6-fold increase in DHA) 
(88). The clinical implications suggest the anti-inflammatory effects of n-3 
fatty acids may not be desirable in healthy older individuals because of the 
suppression of the cell-mediated immune response observed. 
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 As stated previously, nutrients especially vitamin E have been 
observed to play a significant role in the immune response. The studies 
that have not observed significant T cell inhibition with n-3 
supplementation involved an additional supplementation with a high dose 
of vitamin E (205 mg of α-tocopherol) (89). Another factor that may play a 
role in lymphocyte function may be the type of fatty acid supplemented. 
Some studies have observed no effect on T lymphocyte proliferation when 
supplementing with only DHA at 6 g per day for 12 weeks (90). This 
suggests DHA may have selective effects on immune response because 
although lymphocytes were unchanged, the production of pro-
inflammatory cytokines IL-1β and TNF-α were inhibited and NK cell activity 
was also significantly reduced after 3 months in a repeat study (91). In 
analyzing the roles of other n-3 fatty acids, some indices of an altered cell-
mediated immune response were observed. When ALA is supplemented 
via flax-seed oil diets for 8 weeks, the in vitro proliferation of peripheral 
blood mononuclear cells was significantly reduced compared to controls 
although no affect in IL-2 secretion or in B cell function (humoral immunity) 
was observed (92). Purified esters of EPA were analyzed exclusively 
without the addition of DHA, and significant inhibition of NK-cell activity of 
peripheral blood lymphocytes was observed with emulsions containing 0.3 
g of EPA (93). Although clinical implications are inconclusive, these studies 
indicate great variability in suppression of immune indices with differing 
omega-3 fatty acids.
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 Immune Response Against Infections. In order to defend against 
pathogens, the innate and adaptive immune responses must operate 
quickly to induce cellular lymphocyte activity. In order for a sufficient 
immune response to occur, the number and functions of lymphocytes is 
important. Several experimental studies in humans have examined the 
immune response to infections with rhinovirus (RV). Increased peripheral 
blood mononuclear cell (PBMC) proliferation, prior to RV-16 inoculation, 
was associated with reduced peak viral shedding (r=-0.62, p<0.005), thus 
infections were reduced. Similar findings were observed with RV-induced 
IFN-ɣ secretion, which was associated with reduced peak viral shedding 
(r=-0.58, p=0.01). This confirms the importance of lymphocyte proliferation 
for sufficient immune responses to RV infections (94). 
 In considering the health state of the individual, lymphocyte 
proliferation may be problematic in conditions where the inflammatory 
response is already heightened. A study by Skoner et al. observed the 
effects on several immune parameters to RV-39 infections in patients with 
allergic rhinitis (AR) and nonallergic patients. AR patients showed immune 
dysregulation with a lower number of activated helper T cells and poor 
lymphocyte response to RV-39 infection (95). This is evidence that pre-
existing inflammation may alter the ability to fight infections related to 
immune dysregulation. 
 In order to elicit an immune response, T cells depend on dendritic 
cells (DC) for effective antigen presentation. Also, DCs produce TNF-α 
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which stimulates DC maturation to initiate a series of changes that 
produce a T cell response against infections. Immune function against 
influenza virus infection was assessed among healthy older adults 
compared to healthy young adults in an experimental trial. Findings 
showed that older adults had impaired DCs from a dysregulation of 
influenza-specific CD8+ T cells. This is evident from observations of 
decreased proliferation and significantly less TNF-α production compared 
to young adults. DC maturation is essential for a protective immune 
response against viruses and is dependent on the production of TNF-α by 
DCs in older adults (96). 
! The previous investigations have indicated the need of lymphocyte 
proliferation for an effective immune response against infections. However, 
n-3 PUFAs have been shown to decrease lymphocyte proliferation. Fish 
oil supplementation, rich in n-3 FAs, may interfere with the immune 
response to the the rhinovirus infection. 
! Cytokine production. A number of studies have looked at the effects 
of fish oil supplementation on the production of cytokines IL-1β and TNF-
α. In studies supplementing at least 2.4 g or greater of EPA and DHA per 
day in diets of young adults for 4 weeks reported a 25% to 75% decrease 
of in vitro secretion of these cytokines (52,88,89). As reported previously, 
Meydani et al. found a reduction of inflammatory IL-1β, TNF-α, and IL-6 
cytokine secretion by 24, 40, and 46% respectively in adults over the age 
of 40 consuming a low-fat, high-fish diet (1.2 g of EPA and DHA per day) 
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for 24 weeks. Conversely, the low-fat and low-fish diet (0.27 g of EPA and 
DHA per day) group modestly increased production of IL-1β and TNF-α 
secretion but had no effect in IL-6 secretion (87).
 The anti-inflammatory effects of omega-3 supplementation with at 
least 2.3 g of EPA plus DHA per day showed a reduction of the 
inflammatory cytokines TNF-α, IL-1, IL-2, IL-6, and IFN-ɣ secreted from 
mononuclear cells (97). However, there is a large discrepancy in the 
immunomodulatory effects of omega-3 PUFAs in human immune function 
with many studies varying in the amount of fish oil supplemented from 
modest to high doses. The reason for such conflicting results of the 
immunosuppressive effects of omega-3 fatty acids may be due to study 
design, cytokine measurement methods, and differing subject 
characteristics (5). More careful analyses of the results of these studies 
should be taken into consideration.
 Current Evidence. The immunosuppressive effects of omega-3 fatty 
acids have been extensively observed in the human population in regards 
to lymphocyte proliferation and cytokine production. These measured 
immune responses are vital in addressing the anti-inflammatory nature of 
omega-3 PUFAs however, the immune response to infections in healthy 
adults has not been evaluated. There are several studies addressing this 
issue in animals suggesting that the immunosuppressive nature of fish oils 
EPA and DHA may be detrimental to the health of individuals exposed to 
viral infections (10-12).
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 Byleveld et al. demonstrated that fish oil consumption in mice 
impaired host resistance to infection with influenza (11). For fourteen days 
mice were fed either the control diet of 3 g of sunflower oil plus beef tallow 
per 100 g of diet or the experimental diet of 17 g of FO per 100 g of diet 
before being inoculated with the live influenza virus. These levels of FO 
are comparable to amounts consumed by supplementing adults on a per 
weight basis. After 5 days of infection, the FO group had significantly 
greater viral load, lowered body weights, and consumed less food 
compared to the control group. Other significant observations of immune 
indices in the FO group were observed such as impaired production of 
lung IFN-ɣ cytokine, serum immunoglobulin (Ig) G and lung Ig A-specific 
antibodies; however, lung IFN-α/β and CD4 and CD8 T lymphocytes did 
not significantly differ between groups. These results suggest that FO may 
not affect IFN-α/β in the first line of defense but can affect IFN-ɣ once T 
cells are presented to the antigen (11). 
 In a similar study as stated previously, Byleveld et al. also 
examined the effects of FO diets on cytotoxicity and lymphocyte 
proliferation (10). For 14 days mice were fed either 17 g of FO or beef 
tallow with 3 g of sunflower oil per 100 g of diet before infection with the 
influenza virus. It was found that lung virus-specific T lymphocytes were 
significantly lower in FO fed mice although bronchial lymph node cell 
proliferation was significantly higher. In addition, it was found that spleen 
cell proliferation was significantly higher in the FO fed mice. The authors 
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believe that these results help to explain the delayed viral clearance that 
was found in FO fed mice (10). 
 Other researchers examined dietary fish oils and their 
immunosuppressive effects in response to influenza virus infection. 
Schwerbrock et al. studied mice fed diets of 4 g of FO plus 1 g of corn oil 
per 100 g of diet or a control diet of 5 g of corn oil per 100 g of diet for 2 
weeks. The FO fed mice had lower lung inflammation compared to 
controls, but they experienced a 40% higher mortality rate and a 70% 
higher lung virus load observed as well. FO fed mice also had a longer 
recovery period after infection. Similar to Bylevleld's results (10), splenic 
natural killer (NK) cell activity was impaired in the FO fed mice but lung NK 
activity was not altered. The FO fed mice also had significantly lower CD8 
T lymphocytes and reduced mRNA expression of inflammatory protein-1-
α,TNF-α, and IL-6 (12). 
 Based on the significantly suppressed immune responses in 
influenza-infected mice, a detrimental effect of fish oils might be the 
contributing factor to the results discussed above.
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Chapter 3
METHODOLOGY
Subjects & Study Design. Healthy women at Arizona State 
University between the ages of 18 and 38 were recruited through email 
announcement (Appendix B) using Arizona State University ListServs and 
printed fliers. Interested subjects were referred to an online survey 
(Appendix C) to determine eligibility based on diet, physical activity, 
medical history, self-reported anthropometric measurements, and ability to 
meet at Arizona State University’s downtown campus on 4 separate 
occasions. Eligible subjects were contacted to schedule a screening visit 
(study visit 1).  
Exclusion criteria included regular smoking (use of >10 cigarettes 
per day), BMI >30 or BMI <18.5, regular use of fish oil supplements, 
regular consumption of one or more 3.5 ounce servings of fish per week, 
and vegetarians who excluded all meat, fish, and poultry from their diet. 
We also excluded individuals who used prescription medications that may 
interfere with body weight such as thyroid medications, and/or regular use 
of anti-inflammatory corticosteroids or non-steroidal anti-inflammatory 
drugs. Women who were pregnant or lactating, individuals who had 
immunity for the seasonal flu, those who had a seafood allergy, as well as 
competing and/or training athletes who engaged in vigorous exercise 
more than 5 times per week were also excluded. 
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To determine a sample size, a power analysis was calculated using 
a probability of 0.05 and a power of 0.8. An average standard deviation of 
25.9 was used based on several parallel studies that measured mean cold 
symptom changes after administration of a dietary supplement. A verified 
sample size calculator was used to determine the calculated subjects 
needed (98). Based on the averages of the calculated sample size and 
previous studies’ sample sizes, a total of 47 participants appeared to be 
sufficient (Appendix D).
After completing the written consent (Appendix E), baseline 
anthropometric measurements, including weight, height, and percent body 
fat, were measured for an accompanying study. Height and weight were 
measured using a stadiometer and calibrated scale, respectively. BMI and 
percent body fat were determined using a bioelectrical impedence 
(Tanita). A brief medical history questionnaire and a validated food 
frequency questionnaire (FFQ) for dietary omega-3 fatty acids (Appendix 
F) were also completed after written consent (study visit 1). 
Qualifying subjects entering the 8-week trial were then stratified 
based on age, BMI, weight, and omega-3 fatty acid consumption via FFQ 
and randomly assigned to either the experimental (FO, fish oil) or control 
(CO, coconut oil) group. Random assignment to groups was performed by 
flipping a coin. Supplements were administered using a double-blind 
procedure. Subjects received either a placebo of CO (1000 mg/softgel) or 
FO (600 mg EPA + DHA/capsule); both gel capsules were similar in size 
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and shape and delivered to the subjects in compliance to the double-blind 
procedure in which only the primary investigator knew the difference. 
Subjects in the control group were instructed to ingest one softgel of 
Puritan’s Pride Natural Coconut Oil (1000 mg) per day. Subjects in the 
experimental group were instructed to ingest one capsule of USP-Certified 
Energy First Omega-3 Fish Oil (400 mg of EPA and 200 mg of DHA/
capsule) per day, preferably with food. Compliance was assessed by 
capsule counts at weeks 4 and 8 and also by calendar checks (Appendix 
F). We controlled for the consumption of dietary sources of omega-3 fatty 
acids by stratifying the subjects based on their responses from the FFQ on 
how often they consumed foods such as fish, seaweed, flaxseed, walnuts, 
etc. 
At week 1 of the intervention (study visit 2), all subjects received a 
booklet containing copies of the Wisconsin Upper Respiratory Symptom 
Survey-21 (Appendix F) to record their illness symptoms and the use of 
any over-the-counter supplements and/or medications taken to relieve 
their illness symptoms each day. Copies of the Godin Leisure-Time 
Exercise Questionnaire to assess weekly physical activity were also 
included in the booklet (Appendix F). An explanation and practice session 
took place at week 1 (study visit 2) to ensure proper usage of the 
questionnaires and to answer any questions from the subjects. A 24-hour 
dietary recall (Appendix G) was also administered at week 1 to check 
compliance for eliminating other dietary sources of omega-3 fatty acids 
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throughout the study. Compliance to the supplements and surveys were 
checked bi-weekly through email from a blinded Master’s list of subjects’ 
first names and emails. Survey booklet compliance was checked at week 
4 (study visit 3), and subjects received a new booklet to record symptoms 
for weeks 5-8. Subjects returned booklets at week 8 (study visit 4). A 
second 24-hour dietary recall and omega-3 fatty acid FFQ were completed 
(study visit 4). Fasting blood samples (no food or drink with the exception 
of water for 8 hours) for the measurement of the inflammatory marker 
tumor necrosis factor-alpha (TNF-α) were drawn at weeks 1 and 8. 
Blood Analysis. Blood marker TNF-α was analyzed using Human 
Quantikine Immunoassay ELISA kit, which employs the quantitative 
sandwich enzyme immunoassay technique. Plasma blood samples were 
collected with EDTA as an anticoagulant. Within 30 minutes of collection, 
samples were centrifuged at 1000 x g for 15 minutes, plasma was 
separated and stored at ≤ 20° C until analysis. Samples were analyzed 
within 7 days of collection (99) (Appendix H). 
Wisconsin Upper Respiratory Symptom Survey-21. The Wisconsin 
Upper Respiratory Symptom Survey (WURSS-21) is a standard and 
evaluative measure of the symptoms associated with the common cold 
(Appendix F). The survey consists of 21 questions: a global severity 
indicator, 19 symptom-severity items measured on a 7-point severity 
scale, and one question comparing symptom severity to the previous day. 
In this study we used a modified version of the WURSS-21 which is a 
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tested, reliable, and valid method for analyzing the incidence, severity, and 
duration of the common cold (100). 
The WURSS-21 assessed symptom severity on a 7-point scale 
where 1 is considered to be very mild, 3 is mild, 5 is moderate, and 7 is 
severe. In this study, summing the scores from the first 10 questions 
provided a measure of sickness severity, summing the scores from the 
next nine questions provided a measure of functional impairment, and 
summing all 19 items provided a measure of a global sickness severity. 
Statistical Analysis. We performed statistical analysis using the 
SPSS Statistical Analysis system 20.0 and dietary analysis using Food 
Processor SQL (version 10.10). Data were reported as means ± standard 
error (SE). To compare the differences in means of outcome variables we 
used the two-tailed independent t-test or Chi-Square tests. Nonparametric 
measures were used if data were not normally distributed. Differences 
were considered significant at p≤0.05.
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Chapter 4
DATA & RESULTS
 Subject recruitment for this trial took place throughout January and 
February, 2012 at Arizona State University’s downtown Phoenix campus. 
The online survey was completed by 163 prospective subjects, of which 
only 53 were contacted due to exclusion criteria (Figure 2). Out of the 110 
participants the major reasons for exclusion were consuming 3.5 oz. 
servings of fish more than once per week (41%), vegetarian status 
(14.5%), taking fish oil supplements regularly (7.3%), having immunity for 
the seasonal flu (7.3%), and a reported BMI >30 (kg/m2) (6%). After 
contacting 53 respondents to schedule the screening visit, 18 people did 
not respond. A total of 35 females were enrolled in the study, stratified by 
age, BMI, weight, daily n-3 fatty acid intake from FFQ, and randomly 
assigned to either the experiment (FO) or control (CO) group. This 
resulted with 18 subjects assigned to the FO group and 17 subjects in the 
CO group. Throughout the course of the study, 9 subjects were lost to 
follow-up visits due to canceling week 1 visit (n=1), not showing up to 
week 1 visit (n=4), scheduling conflicts (n=2), or intention for weight-loss 
(n=2). The remaining 26 subjects who completed the study were used for 
data analysis (FO, n=13; CO, n=13). There was 92.8% compliance 
throughout weeks 1-8 for all subjects taking the pills. Softgel capsules 
counted at weeks 4 and 8 verified that participants adhered to the 
protocol, assuming all capsules not counted were consumed.
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Completed online survey
n=163
   Contacted   Excluded
   n=53    n=110
 
 No response  Scheduled screening visit 
 n=18    n=35
     
    Randomization
     n=35
  Experiment group         Placebo group
  n=18           n=17
 Lost  Completed  Completed     Lost
 contact Trial   Trial      contact
 n=5  n=13   n=13      n=4
Figure 2. Trial flow chart of subject attrition 
Screening variables measured upon enrollment of the study were 
analyzed using independent samples t-tests, which indicate no significant 
differences between FO and CO groups at baseline (Table 1). Age ranged 
from 18 to 38 years, with the mean age being similar in both groups (24.0 
± 1.6 years for FO and 23.0 ± 1.7 years for CO). Subjects were stratified 
on baseline variables of age, weight, BMI, and daily n-3 intake from FFQ. 
Other variables did not differ significantly between groups, including 
percent body fat, TNF-α, alpha-linolenic acid (ALA), and linoleic acid (LA) 
from 24-hour recalls on study visit 2. 
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 Table 1. Baseline Characteristics of Participants1
ALL (n=26) FO (n=13) CO (n=13) P-value
Age2 (y) 23.5 ± 1.1 24.0 ± 1.6 23.0 ± 1.7 0.339
Weight (lb) 144.2 ± 4.4 140.7 ± 6.1 147.6 ± 6.5 0.424
Height (in) 65.4 ± 0.5 65.3 ± 0.7 65.5 ± 0.6 0.815
BMI (kg/m2) 23.7± 0.6 23.2 ± 0.8 24.2 ± 0.9 0.424
Body Fat (%) 29.2 ± 1.3 28.4 ± 2.0 30.1 ± 1.8 0.520
TNF-α (pg/mL) 1.9 ± 0.4 (n=19)
2.4 ± 0.7      
(n=8)
1.4 ± 0.4 
(n=11) 0.205
FFQ n-3 intake2 
(g/d) 0.55 ± 0.08 0.68 ± 0.14 0.43 ± 0.07 0.137
ALA 24-hr recall2 
(g/d) 0.53 ± 0.10 0.50 ± 0.11 0.55 ± 0.18 0.573
LA 24-hr recall2 
(g/d) 4.87 ± 0.91 4.80 ± 1.17 4.95 ± 1.45 0.778
1Values reported as means ± SE. ALL - all subjects; FO - fish oil group;  
CO - coconut oil group; FFQ- food frequency questionnaire; ALA - α-
linolenic acid; LA - linoleic acid
2Data analysis by nonparametric independent samples t-test (Mann-
Whitney U); all other analyses by independent t-test
The subjects were selected based on self-reported low fish 
consumption, and we tracked ALA (n-3) fatty acid intake at screening 
(week 0) and at week 8 through a specialized FFQ (Table 2). Additionally, 
24-hour recall records detailed any changes in LA (n-6) and ALA 
consumption at week 1 and week 8 among participants. Based on these 
measures, there were no significant changes in dietary LA and ALA 
consumption between FO and CO groups over the course of the study. 
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Table 2. Dietary Data at Weeks 0, 1, and 81,2
Week 0 Week 1 Week 8 P-value3
ALA acid (n-3) intake (g/d), FFQ
ALL 0.55 ± 0.08 ND 0.60 ± 0.10
FO 0.68 ± 0.14 ND 0.58 ± 0.14
0.174CO 0.42 ± 0.07 ND 0.63 ± 0.16
ALA acid (n-3) intake (g/d), 24-hr recall
ALL ND 0.50 ± 0.10 0.55 ± 0.12
FO ND 0.48 ± 0.11 0.62 ± 0.21
0.975CO ND 0.53 ± 0.17 0.48 ± 0.12
LA acid (n-6) intake (g/d), 24-hr recall
ALL ND 4.83 ± 0.90 4.81 ± 0.84
FO ND 4.75 ± 1.15 5.09 ± 1.31
0.778CO ND 4.92 ± 1.44 4.53 ± 1.10
1ALA - alpha-linolenic acid; LA - linoleic acid; ALL - all subjects (n=26); FO 
- fish oil group (n=13), 400 mg/d EPA + 200 mg/d DHA; CO - coconut oil 
group (n=13), 1000 mg/d coconut oil; ND - no data 
2Values reported as means ± SE; values do not include supplemental fish 
oil 
3Data analysis by nonparametric independent samples t-test for change 
over time (Mann Whitney U)
Due to costs, blood analysis of the plasma inflammatory marker, 
TNF-α, was performed on a total of 19 randomly selected samples (FO, 
n=8; CO, n=11). There was a strong correlation with TNF-α concentrations 
(Table 3) for weight (r=0.480, p=0.037) (Figure 3), BMI (r=0.481, p=0.037) 
(Figure 4), and percent body fat (r=0.511, p=0.025) (Figure 5). The 
baseline levels of TNF-α did not differ between groups, and the 
intervention did not change TNF-α concentrations (Figure 6). Over the 
course of the trial, there was not a significant change in TNF-α 
concentrations seen between CO and FO groups  (0.84 pg/mL vs 0.74 pg/
mL, p=0.482) (Table 4,Figure 7). 
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Table 3. Correlations Among Baseline Variables and 
TNF-α (pg/mL)1
Variable
Pearson 
correlation 
coefficient (r)
P-value2
Weight (lb) 0.480 0.037
BMI (kg/m2) 0.481 0.037
Body Fat (%) 0.511 0.025
1Data analysis performed on 19 subjects
2Statistically significant at the 0.05 level
Figure 3. Relationship between baseline TNF-α concentration and body 
weight
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Figure 4. Relationship between baseline TNF-α concentration and BMI
Figure 5. Relationship between baseline TNF-α concentration and body 
fat percentage
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Figure 6. Comparison of baseline TNF-α concentrations between groups
 Data did not change from baseline after intervention, no 
 subjects moved across the cut-off point of 1.36 pg/mL (101)
Table 4. Plasma TNF-α Levels (pg/mL) at Weeks 1 and 81,2
ALL (n=19) FO (n=8) CO (n=11) P-Value3
Week 1 1.85 ± 0.37 2.42 ± 0.65 1.44 ± 0.42
0.482Week 83 2.65 ± 0.71 3.16 ± 1.02 2.28 ± 1.00
Reported range for healthy controls4:  0.60 - 6.40 pg/mL
1ALL - all subjects; FO - fish oil group; CO - coconut oil group
2Values reported as means + SE; range for entire sample: 0 - 5.59 pg/mL
3Data analysis by nonparametric independent samples t-test for change 
over time (Mann-Whitney U)
4Reported levels of plasma TNF-α from ELISA assays observed in 
healthy controls (102) 
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Figure 7. Comparison of changes in mean TNF-α concentrations from 
week 0 to week 8 between groups
 The daily cold symptom survey used to record common cold 
symptoms during the 8 week trial was the Wisconsin Upper Respiratory 
Symptom Survey-21 (WURSS-21) (Table 5). The scores are arbitrary 
units of measure that represent the degree of symptoms. The first 10 
questions on the survey assessed common symptoms including runny 
nose, sneezing, sore throat, cough, head congestion, and fatigue. A 7-
point Likert scale was used to indicate the severity of each symptom and a 
sum of all 56 days calculated the total symptom severity score. The overall 
compliance for completing the cold symptom survey each day was 98.2% 
among all participants. 
! Analysis was performed by taking the average symptom scores 
over 8 weeks in 4-day increments. No significant differences were 
observed for all fourteen 4-day averages between groups. Overall, the FO 
group displayed a lower average perception of symptoms than did the CO 
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group, but this difference did not achieve statistical significance (p=0.418) 
(Figure 8).
Table 5. WURSS-21 Analysis of 4-Day Mean Cold Severity Symptoms1,2
Day ALL (n=26) FO (n=13) CO (n=13) P-value3
4 5 ± 2 7 ± 2 4 ± 2
8 3 ± 2 5 ± 3 2 ± 1
12 4 ± 2 3 ± 3 4 ± 2
16 5 ± 2 4 ± 2 6 ± 3
20 7 ± 3 4 ± 3 10 ± 4
24 5 ± 2 3 ± 2 7 ± 4
28 3 ± 1 2 ± 1 4 ± 2
32 1 ± 1 2 ± 1 1 ±  0.5
36 2 ± 1 1 ± 1 3 ±  2
40 2 ± 1 2 ± 2 2 ± 1
44 1 ± 1 2 ± 2 0.5 ± 0
48 3 ± 2 5 ± 4 0.5 ± 0
52 2 ± 1 3 ± 2 1 ± 1
56 3 ± 2 2 ± 1 5 ± 3
Total Weeks 1-8 176 ± 44 167 ± 71 185 ± 56 0.418
Weeks 1-4 31 ± 9 27 ± 12 36 ± 13 0.479
Weeks 5-8 15 ± 6 17 ± 11 12 ± 5 0.724
1WURSS-21 - Cold symptom survey; ALL - all subjects; FO - fish oil 
group; CO - coconut oil group
2Values reported as means ± SE; Units are arbitrary measure of 
magnitude
3Analysis by nonparametric independent samples t-test (Mann Whitney 
U) 
 Analysis of the first and second halves of the trial was performed to 
assess any changes at midpoint, which is believed to be the time when 
fish oils are effectively incorporated into plasma membranes. Observed 
among all participants was a decrease in cold symptom severity scores 
from the first half (weeks 1-4) to the second half (weeks 5-8) of the trial 
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(Table 5; Figure 8). However, the CO group decreased more dramatically 
(67%) than the FO group (37%) from the first half of the study, although 
not statistically significant (p=0.572).
 Figure 8. Comparison of mean cold symptom severity scores between 
groups over course of the study. 
! Units are an arbitrary measure of magnitude. Symptom scores are 
 reported as 4-day averages (1=very mild; 3=mild; 5=moderate; 
 7=severe). (   FO) (  CO)
! The WURSS-21 also gave insight into how the subject was feeling 
in regard to a URTI illness, measured as the global severity indicator. Data 
were coded as yes or no for each analysis. No significant differences were 
observed between FO and CO groups in all analyses with the WURSS-21 
(Figure 9).
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 Figure 9. Analysis of WURSS-21 global severity indicator, assessing 
those not sick or sick with a URTI. Analysis of the incidence of cold 
symptoms, assessing those with no symptoms or having cold symptoms. 
Data represent percentages of all subjects (n=26) analyzed between 
groups from the first (weeks 1-4) and second (weeks 5-8) half of the trial. 
P-values represent Chi-square (continuity correction values) for 2x2 
tables. 
 1WURSS-21 - Cold symptom survey; URTI - Upper respiratory tract 
 infection
WURSS-21 Global Severity Indicator1
Incidence of Cold Symptoms
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 To assess the severity of the colds, an analysis of reported cold 
symptoms greater than or equal to moderate magnitude was performed 
(Figure 10). There was no difference between reporting of symptoms 
between groups from weeks 1-4 and weeks 5-8. Of those who reported a 
cold, the incidence of that cold being moderate to severe was also 
analyzed. No significant differences were observed between groups who 
reported moderate to severe cold symptoms.
 In order to control for other factors interfering with the inflammatory 
state, reported use of NSAIDs, other medications, and total caffeinated 
and alcoholic beverages were tracked with yes or no responses to 
questions added to each daily survey. There were no association of these 
potential confounding variables with the outcome measures of changes in 
TNF-α concentration and cold severity symptom scores over time, thus 
they were not controlled for during data analysis. 
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 Figure 10. Analysis of the incidence of cold symptoms being moderate or 
above and reported colds that were severe, assessing subjects’ 
perception of colds being less than moderate and their perception of colds 
being moderate to severe. Data analyzed between groups from the first 
(weeks 1-4) and second (weeks 5-8) half of the trial. P-values represent 
Chi-square (continuity correction values) for 2x2 tables. Error bars show 
95% confidence interval.
 1Data represent percentages of all subjects (n=26)
 2Data represent percentages of subjects reporting cold 
 symptoms during Weeks 1-4 (n=18) and Weeks 5-8 (n=15)
Incidence of Moderate-Severe Cold Symptoms1
Reported Colds that Were Severe2
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Chapter 5
DISCUSSION
 In this double-blind, placebo-controlled, randomized trial, 8-weeks 
of FO supplementation (400 mg EPA + 200 mg DHA per day) did not 
increase the risk for cold infections compared to placebo (1000 mg 
coconut oil per day). When all data were considered, reporting of cold 
severity symptoms in CO was 11% greater than FO although these results 
are not significant. Results from this current study do not negate the 
American Heart Association’s current dietary recommendations to 
consume 3.5 oz of fish twice per week.
 The incidence of symptoms related to URTIs in healthy females 
consuming 600 mg of fish oil per day does not agree with the infectious 
risks seen in animal studies. This is the first known study in humans to 
examine the incidence of cold symptoms with FO supplementation and the 
data are inconclusive. Overall, it appears the controls had more cold 
severity symptoms however, looking at the first and second half of the 
study it does not appear that way. Infected mice showed adverse effects in 
regard to increased viral load, increased mortality (12), and decreased 
cytotoxic T cell activity (10,11) while fed FO diets. A longer trial may be 
necessary to better examine the relationship between FO consumption 
and infection risk in humans. 
 It is important to consider the time needed for incorporation of fish 
oils into plasma phospholipid membranes. A number of placebo-controlled 
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studies have examined the effects of FO supplementation with EPA + 
DHA, EPA, or DHA fatty acids on changes of plasma phospholipid 
concentrations after supplementation. Cao et al. examined healthy men 
and women consuming 2.16 g (1296 mg EPA + 864 mg DHA) per day for 
8 weeks and found a 5% increase in EPA + DHA concentrations in plasma 
phospholipid membranes, although no statistic significance was observed 
(40). Rees et al. showed a mean increase of 1.8% in EPA plasma 
phospholipid concentrations after 12 weeks of supplementation with 1.35 
g of EPA per day in young healthy men, which was significantly different 
than controls (p<0.02) (103). Thirdly, Kew et al. studied EPA (4.7 g/d) and 
DHA (4.9 g/d) supplementation separately for 4 weeks in healthy subjects 
and showed a mean increase of 5.8% in EPA and 7.5% in DHA 
concentrations, with each group respectively (p<0.05) (104). It is important 
to consider the amount of EPA and DHA supplemented and the length of 
the study (4, 8, and 12 weeks), but these studies provide evidence to 
support the dose-dependent changes of EPA and DHA in plasma 
phospholipid concentrations after 4 weeks of supplementation.  
 Thus in the present study, it might be more relevant to account for 
FO after 4 weeks, which is the second half of the study (Weeks 5-8). 
However, looking at the data from the first and second half of the trial, 
there was a larger decrease in cold symptoms in the CO group. The FO 
group decreased 37% whereas the CO group decreased 67% (Table 5), 
although data are not significant. More research is needed to determine 
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what effects moderate-dosage of FO supplements have on cold 
symptoms. 
 This trial coincided with the common months of cold and flu 
incidences, however the recent 2011-2012 cold and flu season peaked in 
February (Figure 11). Since the peak of the season was at the beginning 
of the study, our outcome measure of cold symptoms was on the down-
fall. These data are based on the Gallup-Healthways Well-being Index, 
surveying 1,000 Americans each day if they had a cold or flu yesterday 
(105). Ideally, the study of cold symptom occurrences should begin in 
December or January to capture the highest reports of colds among 
American adults. 
Figure 11. Year-over-year comparison of self-reported cases of colds from 
the Gallup poll (105).
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 In our study, baseline TNF-α correlated with body weight, body fat 
percentage, and BMI. When all variables are considered, it appears TNF-α 
levels are associated with fat mass in healthy women. Another study 
measured TNF-α using the same assay and showed a positive correlation 
with baseline absolute truncal fat (kg) (r=0.42, p=0.01) and relative truncal 
fat (r=0.54, p<0.01), calculated as truncal fat divided by total body fat 
measured using dual x-ray absorptiometry scans, in healthy young 
controls, healthy elderly controls, or Type-2 diabetics. After considering 
compounding factors such as age, gender, and diabetes, TNF-α continued 
to significantly correlate with relative truncal fat mass (r=0.830, p=0.04) 
(106). Further evidence supports that TNF-α levels are associated with 
visceral fat mass measured using the waist to hip ratio (WHR) in obese 
women, most of whom also showed some level of glucose intolerance 
and/or insulin resistance. TNF-α was strongly correlated with WHR 
(r=0.53, p<0.01) and fasting and post-oral glucose tolerance tolerance test 
(OGTT) insulin levels (r=0.47, p<0.02) (107). However, other observations 
have associated TNF-α levels in both subcutaneous and visceral fat 
tissues. Adipocyte cell size in both tissues were significantly correlated 
with TNF-α in serum and soluble TNF-receptor (sTNFr) 2 production in 
overweight/obese and lean subgroups (108).
 Endogenous production of TNF-α comes from many cell types 
which includes adipose cells and circulating monocytes and lymphocytes 
in the blood (106,109). Evidence indicates TNF-α production increases 
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with increasing adiposity and decreases with decreasing adiposity. TNF-α 
modulates fat metabolism and controls adipocyte size by possibly 
increasing insulin resistance in adipose tissue through paracrine signaling 
(109). Other immune parameters have shown to be elevated in obese 
individuals, such as increased monocytes (110) which may be attributable 
to TNF-α production in adipose tissue. 
 A significant relationship between serum TNF-α concentrations and 
increasing levels of obesity were observed in women with BMI categories 
ranging from 25-30 kg/m2 (6.5 pg/mL, p<0.001), 30-40 (6.8 pg/mL, 
p<0.001), and over 40 (7.4 pg/mL, p<0.001) compared to lean controls 
(2.9 pg/mL) (111). Although the relationship is apparent, we did not expect 
to see anything in our subjects who were screened with a measured BMI < 
30 kg/m2. 
 Plasma TNF-α concentrations measured in the people with chronic 
inflammation, such as in patients with Type-2 diabetes, were significantly 
higher than healthy controls (~2 pg/mL vs. ~1.1 pg/mL, p<0.05) (104). This 
is true for individuals in other chronic inflammatory conditions such as with 
metabolic syndrome and smoking. Compared to healthy controls, 
measured levels of serum TNF-α, using similar methods in the present 
study, in people with metabolic syndrome had 1.45 pg/mL (p<0.001) and 
smokers had 15 pg/mL (p<0.004) (101,112). TNF-α was found to be 
significantly higher in heart disease patients with severe aortic stenosis 
(AS) (2.1 pg/mL) and mitral regurgitation (MR) (1.3 pg/mL) compared to 
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healthy controls (0.7 pg/mL) (p<0.05). AS patients had significantly higher 
TNF-α levels than in MR (p=0.03) and lastly, patients with AS and MR in 
New York Heart Association (NYHA) functional class II had higher TNF-α 
levels and sTNFr 1 and 2 than NYHA class I patients. These findings 
indicate serum TNF-α levels and sTNFr 1 and 2 are elevated in patients 
with clinically significant hemodynamic pressure and volume overload 
(113). A number of factors could contribute to the variability in measured 
TNF-α concentration such as possible polymorphisms in genes that 
influence TNF-α production (114), inter-assay or intra-assay variabilities, 
measuring soluble TNF receptors instead of concentrations, or the 
medium that TNF-α was measured from such as serum/plasma or cell 
culture supernates. 
 Gurrorala et al. determined a cut-off point related to the change in 
the clinical parameter of high density lipoprotein cholesterol (HDL-c) levels 
with TNF-α concentration. Significantly higher incidences of TNF-α levels 
greater or equal to 1.36 pg/mL were observed with HDL-c levels less than 
35 mg/dL (p<0.05) in those with metabolic syndrome compared to healthy 
controls (101). The present study observed similar associations with TNF-
α and HDL-c levels such that baseline HDL-c had a medium-strength 
inverse correlation with TNF-α (r=-0.496, p=0.101), although not 
significant. At baseline, 58% of all subjects had TNF-α levels above 1.36 
pg/mL (Figure 12). It is unknown what metabolic conditions could explain 
this descriptive characteristic since subjects were screened with no 
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unresolved health issues. Nonetheless, these findings validate the assay 
that TNF-α is strongly related to body fat and inversely associated with 
HDL-c levels, which coincides with that reported in the literature 
(101,106-108). 
 Figure 12. Percentage of participants with TNF-α above the clinical 
parameter at baseline. 
 Intervention did not change TNF-α concentrations above or below 
 the clinical parameter 1.36 pg/mL 
 Future studies should consider measuring plasma concentrations of 
EPA, DHA, and AA fatty acids at multiple points throughout the trial. This 
could have effectively monitored compliance to protocol and assess the 
time-frame for which plasma saturation of fatty acids occurred. 
 There are gender differences to consider in regard to n-3 PUFA 
status. The metabolic conversion of essential ALA into DHA is inefficient in 
humans but more efficient in women (9.1%) compared to men (7.9%) 
(115). It is believed that estrogen is a mediator in the increased conversion 
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of ALA to DHA, possibly due to its role increasing the activity of 
desaturase and elongase enzymes necessary for DHA conversion (116). 
 Since only healthy women were enrolled for in the trial, this limits 
the generalizability of the results especially to males, elderly subjects, 
those with chronic inflammatory conditions, or obese populations. For 
example, the immune response varies with disease state, age, and body 
weight therefore it is difficult to generalize these results to other 
populations.
 The placebo of coconut oil supplemented at 1 g/d, was chosen for 
its trivial effects on metabolic outcomes. It is characteristically high in 
saturated fatty acids and only 6-12 carbons long, making it a medium-
chain triacylglycerol (MCT). MCTs are different than PUFAs in that they do 
not get incorporated into chylomicrons for transport through the lymph to 
be delivered to tissues. Conversely, MCTs are transported directly into the 
cells and metabolized for energy. Other investigators have chosen 
placebo oils such as mineral oil, soybean oil, corn oil (101) and olive oil 
(104) because of their limited bioavailability in low doses and high 
saturated fatty acid content. Studies that used CO to show an effect were 
supplementing 27.4 g/d that improved health outcomes such as 
decreased waist circumference and increased HDL (117) or 29 g of 
coconut oil that showed a decrease in post-prandial glucose and 
increased total cholesterol levels (118). The effects of 27-29 g/d of coconut 
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oil reported in these studies are drastically larger doses than the 1 g/d of 
coconut oil supplemented in the present study. 
 The WURSS-21 is a validated and reliable measure for assessing 
the subjective perception of cold symptoms (100). People may tolerate 
various cold symptoms differently, impacting their self-reported responses 
on the questionnaire. Since cold indices were measured based on the 
subject’s perception of illness, there is a possibility that cold symptoms 
could be confused with other ailments different than cold symptoms such 
as allergies. To avoid confounding symptoms due to allergy, the first 
question on the survey was modified to specify only sickness related to a 
URTI. Additionally, daily tracking of any medications taken and the number 
of caffeinated and alcoholic beverages consumed were accounted for as 
possibly conflicting with the immune response. 
 The weekly dosage of EPA and DHA given in supplement form (4.2 
g) was equivalent to about four servings of 3.5 oz of oily fish per week. 
The types of fish that would be equivalent to the amounts given in the trial 
over the course of a week would be 14 oz of Atlantic salmon, 6.3 oz of 
mackerel, 10.7 oz of herring, and 15 oz of sardines (119). Based on these 
results, the dietary intake of fish, at the dosage of twice the 
recommendations, of approximately 2 oz servings of fish per day, is not 
problematic. The EnergyFirst fish oil supplement instructions were actually 
intended for 3 times the amount given in the trial. The health effects from 
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the instructed supplemental amount of 1.8 g/d EPA + DHA would need to 
be further investigated. 
 Limitations. There are several limitations in this trial. Subject 
adherence to protocol required consuming one supplement and 
completing the cold symptom survey daily. The subjects were not 
instructed to abstain from eating fish in order to avoid fish oil. The pre and 
post FFQs were designed to capture this, thus we are fairly confident of 
subject adherence. The inflammatory response may be impacted from 
external factors such as sleep deprivation and psychological stress. The 8-
week trial duration may not be long enough to reflect long-term effects of 
fish oil supplementation. The timing of the trial did not coincide with the 
peak of the cold and flu season. Although the power analysis suggested 
47 participants, only 26 were analyzed due to recruitment restrictions and 
exclusion criteria which may have hindered observing significant changes. 
Unlike other fish oil supplemented studies, this study did not observe 
detailed mechanisms to determine specific changes of immune indexes. 
This study only measured the incidence of cold symptoms and therefore 
could not control exposure to cold viruses. 
 Strengths. The screening of the subjects was performed on a 
number of exclusion criteria to ensure a homogenous subject pool. Some 
of the inclusion criteria included non-smokers, consumption of fish less 
than once per week, not taking fish oil supplements, not taking 
medications that may interfere with the inflammatory state such as 
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corticosteroids and/or non-steroidal anti-inflammatory drugs, not having a 
seafood allergy, and those who did not receive a 2012 seasonal flu shot. 
The double-blind nature of this trial minimized the placebo-effect and 
investigator bias, preventing the investigators from knowing which 
treatment the subjects were receiving. 
 Conclusion. Moderate doses of fish oil supplementation (0.6 g EPA 
+ DHA per day) for 8 weeks is not problematic for increasing the risk of the 
common cold infection in healthy females. The TNF-α concentrations 
displayed a significant positive correlation with body weight, BMI, and 
percent body fat, providing construct validity to this measure. These 
findings at the level of fish oil supplemented do not appear to cause 
unintentional health consequences and do not refute the current dietary 
recommendations of two 3.5 oz servings per week. However, more 
research is needed to assess realistic levels of fish oil supplementation 
(~1.8 g/d EPA and DHA) with the incidence of colds during the prime cold 
season. 
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Study Study Design N/group
Standard 
Deviation
Change in 
Mean
Calculated 
Subjects 
Needed
Brown et al. (95) Parallel 40 1.48 3.53 8
Johnston et al. (68) Parallel 15 88.5 105 26
Goel et al. (72) Parallel 54 0.73 0.7 38
Barrett et al. (94) Parallel 183 13 28 10
Average  73 25.9 34.3 21
        47
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Initial Contact: Email  
• Sent to Arizona State University ListServs
• Inclusion based upon:
• Gender (women)
• Age (18-40 years old)
• Non-obese
• Invitation to complete internet survey
Internet Survey
• Exclusion based upon: 
• Smoking habits (>10 cigarettes/day)
• Vigorous physical activity (> 5 times/ week)
• Regular fish consumption (>1 serving/week)
• Vegetarian diets
• Fish oil supplementation
• Seafood allergies
• Seasonal flu shot
• Pregnant or lactating
Study Visit 1: Week 0 (Screening)
• Informed consent
• Medical history questionnaire
• Omega-3 food frequency questionnaire
• Height & weight
• Percent body fat and BMI (Tanita)
Study Visit 2: Week 1 (Baseline)
• Weight & percent body fat (Tanita)
• Fasting blood sample
• 24-hour dietary recall
• Survey booklet distribution and explanation
• Capsule distribution and explanation
Study Visit 3: Week 4
• Weight & percent body fat (Tanita)
• Collect remaining capsules
• Collect booklets (Weeks 1-4)
• Distribute weeks 5-8 material (Surveys and Capsules)
• Distribute $10 Gift Cards
Study Visit 4: Week 8
• Weight & percent body fat (Tanita) 
• Fasting blood sample 
• 24-hour dietary recall
• Collect remaining capsules
• Collect booklets (Weeks 5-8)
• Distribute $15 Gift Cards
Stratification &
Randomization
Thursday, August 9, 12
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